Zogenix, INC.: directors' dealings · United States · SEC (Form 4)

About Zogenix, INC.

Zogenix, Inc. was a U.S.-based biopharmaceutical company listed on the American NASDAQ market under the ticker ZGNX and headquartered in the United States, with principal offices in Emeryville, California. The company was founded in 2006 as SJ2 Therapeutics, Inc. and renamed Zogenix later that year. Its core strategy was to research, develop, and commercialize therapies for rare diseases, with a strong emphasis on difficult-to-treat pediatric epilepsy and other high-unmet-need neurological disorders. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1375151/000137515122000015/zgnx-20211231.htm?utm_source=openai)) From an operating standpoint, Zogenix was built around two main programs. The first and most important was FINTEPLA, an oral fenfluramine solution that became the company’s lead commercial asset. The second was MT1621, an investigational therapy for thymidine kinase 2 deficiency (TK2d), a rare and potentially life-threatening mitochondrial depletion disorder. Zogenix’s portfolio was therefore narrow but highly focused, reflecting a classic rare-disease biotech model: concentrate resources on a small number of clinically differentiated assets with meaningful regulatory and commercial potential. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1375151/000137515122000015/zgnx-20211231.htm?utm_source=openai)) In competitive terms, Zogenix operated in a specialized pharmaceutical niche where success depends less on broad primary-care scale and more on clinical efficacy, safety, regulatory exclusivity, physician adoption in expert centers, and payer acceptance. FINTEPLA’s positioning in rare epileptic syndromes such as Dravet syndrome and Lennox-Gastaut syndrome gave the company a differentiated profile within pediatric neurology. That made Zogenix a targeted rare-disease platform rather than a diversified commercial pharma company, with valuation driven primarily by pipeline execution and label expansion rather than by large-volume sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1375151/000137515122000015/zgnx-20211231.htm?utm_source=openai)) A major corporate milestone was Zogenix’s acquisition by UCB. UCB announced the deal in January 2022, launched a tender offer in February 2022, and completed the acquisition on March 7, 2022. The transaction was valued at $26.00 per share in cash at closing, plus a contingent value right tied to a potential European approval milestone for FINTEPLA in Lennox-Gastaut syndrome. As a result, Zogenix ceased to operate as an independent publicly traded company, and its principal asset, FINTEPLA, was folded into UCB’s broader epilepsy franchise. For investors looking at historical SEC insider activity, ZGNX is therefore best viewed as a legacy Nasdaq biopharma name whose public-market story ended with a strategic takeover. ([ucb.com](https://www.ucb.com/newsroom/press-releases/article/ucb-commences-tender-offer-to-acquire-zogenix-inc?utm_source=openai))